Common Glucocorticoid Agents
The most commonly used glucocorticoid agents in clinical practice are hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, and triamcinolone acetonide 1.
Glucocorticoid Agents by Potency
Based on the 2024 European Society of Endocrinology/Endocrine Society guidelines, glucocorticoids are categorized by their physiologic dose equivalents 1:
Short-Acting Agents
- Hydrocortisone: 15-25 mg daily (physiologic dose equivalent)
- Structurally identical to endogenous cortisol
- Shortest duration of action
- Has mineralocorticoid activity 2
Intermediate-Acting Agents
Prednisone: 4-6 mg daily (physiologic dose equivalent)
- Most commonly prescribed oral glucocorticoid
- Requires hepatic conversion to active prednisolone 1
Prednisolone: 4-6 mg daily (physiologic dose equivalent)
- Active form of prednisone
- Can be used interchangeably with prednisone 1
Methylprednisolone: 3-5 mg daily (physiologic dose equivalent)
- Available in oral and parenteral formulations
- Intermediate potency 1
Triamcinolone acetonide: Included in physiologic equivalents
- Commonly used for intra-articular injections
- Particulate formulation with prolonged depot effect 3
Long-Acting Agents
Dexamethasone: 0.25-0.5 mg daily (physiologic dose equivalent)
Betamethasone: Similar potency to dexamethasone
- Available in multiple formulations
- Commonly used for injections 4
Relative Potency Rankings
Research evidence demonstrates three distinct potency groups 5:
Highest potency: Betamethasone, dexamethasone, triamcinolone acetonide
Intermediate potency: Methylprednisolone, prednisolone
Lowest potency: Hydrocortisone
Clinical Considerations
Route-Specific Agents
Oral therapy: Prednisone, prednisolone, methylprednisolone, dexamethasone, and hydrocortisone are all available orally 1.
Parenteral therapy: Hydrocortisone (preferred for stress dosing), methylprednisolone, and dexamethasone are commonly used intravenously 2.
Intra-articular injections: Betamethasone and methylprednisolone are preferred for joint injections due to better safety profiles compared to particulate formulations like triamcinolone acetonide 3, 4.
Important Caveats
Mineralocorticoid activity: Only hydrocortisone has significant mineralocorticoid activity, making it essential for primary adrenal insufficiency. Dexamethasone has no mineralocorticoid activity and is inadequate as sole replacement therapy in primary adrenal insufficiency 2.
Duration considerations: Long-acting agents (dexamethasone, betamethasone) should be switched to shorter-acting agents (hydrocortisone, prednisone) when tapering or when long-acting formulations are no longer needed 1.
Formulation matters: Particulate corticosteroids (triamcinolone acetonide, methylprednisolone acetate) have prolonged tissue residence but higher risks of local complications including chondrotoxicity and tissue atrophy 3.